Journal
FREE RADICAL BIOLOGY AND MEDICINE
Volume 114, Issue -, Pages 33-39Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2017.10.002
Keywords
Down syndrome; GABA; Inhibition; GABAalpha5; Inverse agonist
Funding
- program Investissements d'avenir [ANR-10-IAIHU-06]
- IHU-BBT-MOCONET
Ask authors/readers for more resources
Down syndrome (DS), also known as trisomy 21, is the most common genetic cause of intellectual disability. It is also a model human disease for exploring consequences of gene dosage imbalance on complex phenotypes. Learning and memory impairments linked to intellectual disabilities in DS could result from synaptic plasticity deficits and excitatory-inhibitory alterations leading to changes in neuronal circuitry in the brain of affected individuals. Increasing number of studies in mouse and cellular models converge towards the assumption that excitatory-inhibitory imbalance occurs in DS, likely early during development. Thus increased inhibition appears to be a common trend that could explain synaptic and circuit disorganization. Interestingly using several potent pharmacological tools, preclinical studies strongly demonstrated that cognitive deficits could be restored in mouse models of DS. Clinical trials have not yet provided robust data for therapeutic application and additional studies are needed. Here we review the literature and our own published work emphasizing the over-inhibition hypothesis in DS and their links with gene dosage imbalance paving the way for future basic and clinical research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available